Digistain: A Novel, Rapid, and Cost-effective Prognostic Marker for Guiding Adjuvant Therapy in ER+, HER2-Breast Cancer

被引：0
|
作者：
Amrania, Hemmel [1 ]
机构：
[1] Imperial Coll London, Harrow, Middx, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387998
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [1] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [2] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2-breast cancer
    Ragusi, Max A. A.
    Winter-Warnars, Gonneke A. O.
    Wesseling, Jelle
    Linn, Sabine C.
    Beets-Tan, Regina G.
    van der Velden, Bas H. M.
    Elias, Sjoerd G.
    Gilhuijs, Kenneth G. A.
    Loo, Claudette E.
    BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1123):
  • [4] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Dysregulated expression of repetitive DNA in ER+/HER2-breast cancer
    Yandim, Cihangir
    Karakulah, Gokhan
    CANCER GENETICS, 2019, 239 : 36 - 45
  • [6] APOBEC driving genomic evolution in ER+/HER2-breast cancer
    Bos, M.
    Smid, M.
    Sleijfer, S.
    Martens, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S105 - S106
  • [7] TMEM doorway score as a predictive biomarker for therapy selection in ER+/HER2-breast cancer
    Parmar, Priyanka
    Miller, Andrew
    Karadal-Ferrena, Burcu
    Shukla, Suryansh
    Huang, Cien
    Ginsberg, Mindy
    Rosenbaum, Chedva
    Felder, Malka
    Zhang, Chenxin
    Condeelis, John S.
    Xue, Xiaonan
    Rohan, Thomas E.
    Sparano, Joseph A.
    Anampa, Jesus D.
    Entenberg, David
    Oktay, Maja H.
    CANCER RESEARCH, 2024, 84 (22)
  • [8] Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2-breast cancer
    Dodaran, Maryam Soleimani
    Borgoni, Simone
    Sofyali, Emre
    Verschure, Pernette J.
    Wiemann, Stefan
    Moerland, Perry D.
    van Kampen, Antoine H. C.
    BMC CANCER, 2020, 20 (01)
  • [9] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
12345